$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Why is vandetanib called a "special" targeted drug?
2025-10-19 11:44:20
Check Details
Is paclitaxel a targeted drug, and what is its mechanism of action?
2025-10-19 11:44:20
Check Details
2022ASCO Express | Evantumumab combined with lazetinib is expected to break resistance to osimertinib!
2025-10-19 11:44:20
Check Details
2022ASCO Express | Good news for Chinese patients with small cell lung cancer-Rupitidine has remarkable efficacy!
2025-10-19 11:44:20
Check Details
2022ASCO Express | Overall survival is as long as 12.6 months! adagrasib attacks KRAS G12C mutated NSCLC_ Kanghule
2025-10-19 11:44:20
Check Details
How long does it take for lorlatinib to take effect and how to store it?
2025-10-19 11:44:20
Check Details
Which generation of targeted drug is lorlatinib? How effective is it?
2025-10-19 11:44:20
Check Details
The average resistance time to lorlatinib, what drug should be used after lorlatinib resistance?
2025-10-19 11:44:20
Check Details
How effective is lorlatinib?
2025-10-19 11:44:20
Check Details
The difference between ramucirumab and bevacizumab_Canghule
2025-10-19 11:44:20
Check Details
A new generation of new drug adagrasib for the treatment of KRASxa0G12C mutated non-small cell lung cancer
2025-10-19 11:44:20
Check Details
What are the precautions for Tepotinib Hydrochloride Tablets and what are the contraindications for taking them?
2025-10-19 11:44:20
Check Details
1
2
...
3983
3984
3985
3986
3987
3988
3989
...
4155
4156
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
2
Vemurafenib (Zelboraf) Complete Medication Guide
3
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
4
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer
5
Managing Mitotane Resistance in Adrenocortical Carcinoma: Strategies and Global Options
6
Trametinib & Dabrafenib in 2026: A Global Guide to Treating BRAF-Mutant Cancers
7
A Guide to Safely Stopping Mitotane: Why Tapering is Essential and How to Manage
8
Pemigatinib Efficacy: Significantly Improving Survival in FGFR2-Fusion Cholangiocarcinoma
9
Erlotinib: Targeting EGFR Mutations to Precisely Inhibit Non-Small Cell Lung Cancer Growth
10
Tofacitinib: The Role and Considerations of an Oral JAK Inhibitor in Autoimmune Disease Treatment
11
Tucatinib: Redefining the Treatment Landscape for HER2-Positive Cancers with High Selectivity
12
Complete Guide to Garsorasib Resistance Mechanisms and Follow-Up Treatments